TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish "TeleCare North" Pragmatic Cluster-randomized Trial.
Brief Summary: There are two main aims in this study. The first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from COPD that may benefit from telehealth compared with only standard treatment and care. The second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with COPD across patients and municipality districts.

It is hypothesized that telehealth care will increase patients quality adjusted life years at both the cluster and individual level compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. Furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. However, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Options:
A: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Telehealth program; Type: OTHER; Interventions: Other: Telehealth program | Arm Label: Usual care; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Telehealth program; Assigned to Arm(s): Telehealth program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Web Platform | Intervention Type: OTHER; Name: Web Platform; Assigned to Arm(s): Intervention group
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish "TeleCare North" Pragmatic Cluster-randomized Trial.
Brief Summary: There are two main aims in this study. The first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from COPD that may benefit from telehealth compared with only standard treatment and care. The second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with COPD across patients and municipality districts.

It is hypothesized that telehealth care will increase patients quality adjusted life years at both the cluster and individual level compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. Furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. However, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Options:
A: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Control period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: CE marked Philips Motiva system | Intervention Type: DEVICE; Name: CE marked Philips Motiva system; Assigned to Arm(s): Telemonitoring
C: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care
D: Arm Label: COPD, Telehealth; Type: EXPERIMENTAL; Interventions: Device: Telehealth | Arm Label: COPD, Normal clinical practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehealth; Assigned to Arm(s): COPD, Telehealth

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STUDY ON EFFICACY OF UTROGESTAN AS TOCOLYSIS FOR PRETERM LABOR
Brief Summary: RESEARCH HYPOTHESIS

-Incidence of preterm delivery is lower in women treated with oral micronized progesterone (Utrogestan) as acute tocolysis agent compare to Nifedipine group with fewer maternal side effect


Options:
A: Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): B
C: Arm Label: Utrogestan; Type: ACTIVE_COMPARATOR; Interventions: Drug: utrogestan | Arm Label: Nifedipine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: utrogestan; Assigned to Arm(s): Utrogestan | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled SMS Intervention For Improving Medication Adherence in Adult Stroke Patients
Brief Summary: The impact of medications used for secondary stroke prevention relies heavily upon patient adherence. Adherence is defined as "the extent to which a person's behavior - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider." It is said that optimal adherence to medications may reduce the risk of a poor outcome by 26%.

The purpose of this study which is a non-pharmacologic behavioral study is to encourage adherence to medications in stroke survivors by tailored and specific SMS reminders. (Short Text Messages). These SMS reminders will support and assist stroke patients to take medications as prescribed and on time. We hypothesise that SMS will improve the adherence of patients to stroke medications by 2 points on the Morisky Medication Adherence Scale.


Options:
A: Arm Label: self-care promotion; Type: EXPERIMENTAL; Interventions: Other: Multifaceted strategy based on sending text messages(SMS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual outpatient care | Intervention Type: OTHER; Name: Multifaceted strategy based on sending text messages(SMS); Assigned to Arm(s): self-care promotion | Intervention Type: OTHER; Name: Usual outpatient care; Assigned to Arm(s): Control group
B: Arm Label: Intervention-Text messaging; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging; Assigned to Arm(s): Intervention-Text messaging
C: Arm Label: SMS Short Message Service Arm plus Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: SMS- Short Messaging Service | Arm Label: Standard Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS- Short Messaging Service; Assigned to Arm(s): SMS Short Message Service Arm plus Prescription
D: Arm Label: Mobile App Group; Type: EXPERIMENTAL; Interventions: Other: Daily reminders of taking medications, Other: Educational materials | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational materials | Intervention Type: OTHER; Name: Daily reminders of taking medications; Assigned to Arm(s): Mobile App Group | Intervention Type: OTHER; Name: Educational materials; Assigned to Arm(s): Control Group, Mobile App Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled SMS Intervention For Improving Medication Adherence in Adult Stroke Patients
Brief Summary: The impact of medications used for secondary stroke prevention relies heavily upon patient adherence. Adherence is defined as "the extent to which a person's behavior - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider." It is said that optimal adherence to medications may reduce the risk of a poor outcome by 26%.

The purpose of this study which is a non-pharmacologic behavioral study is to encourage adherence to medications in stroke survivors by tailored and specific SMS reminders. (Short Text Messages). These SMS reminders will support and assist stroke patients to take medications as prescribed and on time. We hypothesise that SMS will improve the adherence of patients to stroke medications by 2 points on the Morisky Medication Adherence Scale.


Options:
A: Arm Label: Exercise Prescription + Mobile Health; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Health, Behavioral: Exercise Prescription | Arm Label: Exercise Prescription; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Prescription | Intervention Type: BEHAVIORAL; Name: Mobile Health; Assigned to Arm(s): Exercise Prescription + Mobile Health | Intervention Type: BEHAVIORAL; Name: Exercise Prescription; Assigned to Arm(s): Exercise Prescription, Exercise Prescription + Mobile Health
B: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
C: Arm Label: SMS Short Message Service Arm plus Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: SMS- Short Messaging Service | Arm Label: Standard Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS- Short Messaging Service; Assigned to Arm(s): SMS Short Message Service Arm plus Prescription
D: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With ADHD in a Laboratory Classroom
Brief Summary: This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will enroll to take open-label AR11 BID and undergo dose optimization activities for 8 weeks. Patients who achieve a stable dose during the dose optimization period will continue participation and will be randomized to take double-blind medication (AR11 or placebo) orally twice daily for 1 week. At the end of each double-blind treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom setting utilizing SKAMP and PERMP assessments.


Options:
A: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.; Assigned to Arm(s): N/A
B: Arm Label: Lisdexamfetamine Dimesylate (LDX) 30 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 30 mg | Arm Label: LDX 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 50 mg | Arm Label: LDX 70 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 70 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX 30 mg; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) 30 mg | Intervention Type: DRUG; Name: LDX 50 mg; Assigned to Arm(s): LDX 50 mg | Intervention Type: DRUG; Name: LDX 70 mg; Assigned to Arm(s): LDX 70 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AR11 (amphetamine sulfate) (1 week) - double blind; Type: EXPERIMENTAL; Interventions: Drug: AR11 | Arm Label: Placebo (1 week) - double blind; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AR11; Assigned to Arm(s): AR11 (amphetamine sulfate) (1 week) - double blind | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (1 week) - double blind
D: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence
Brief Summary: This study will investigate a treatment strategy in which a computer-assisted behavioral intervention will be used to help individuals stop their use of cocaine. A medication will be combined with the behavioral treatment among those individuals who do not respond to the behavioral intervention alone. The primary hypothesis of the study is that among cocaine dependent individuals who fail to respond to an initial trial of behavioral therapy, a greater proportion of individuals will benefit from the combined treatment (behavior therapy plus medication) compared to individuals in the comparison group.


Options:
A: Arm Label: Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER); Type: EXPERIMENTAL; Interventions: Behavioral: Computer-assisted behavior therapy, Drug: Mixed-Amphetamine Salts- Extended Release (MAS-ER) | Arm Label: Computer-assisted CBT plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Computer-assisted behavior therapy, Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Computer-assisted behavior therapy; Assigned to Arm(s): Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER), Computer-assisted CBT plus placebo | Intervention Type: DRUG; Name: Mixed-Amphetamine Salts- Extended Release (MAS-ER); Assigned to Arm(s): Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Computer-assisted CBT plus placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual (TAU) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Treatment as usual (TAU), Behavioral: CBT for CBT | Intervention Type: OTHER; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: CBT for CBT; Assigned to Arm(s): 2
C: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as usual + CBT4CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT4CBT | Intervention Type: BEHAVIORAL; Name: CBT4CBT; Assigned to Arm(s): Treatment as usual + CBT4CBT
D: Arm Label: cognitive function rehabilitation group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive function rehabilitation and bias modification | Arm Label: cognitive bias modification group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive function rehabilitation and bias modification | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: cognitive function rehabilitation and bias modification; Assigned to Arm(s): cognitive bias modification group, cognitive function rehabilitation group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
Brief Summary: To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy


Options:
A: Arm Label: Group1; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group2; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group3; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group4; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group5; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331), Other: Placebo | Intervention Type: DRUG; Name: nemolizumab (CIM331); Assigned to Arm(s): Group1, Group2, Group3, Group4, Group5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group5
B: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg, Placebo
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: German: Effekte Eines Telemonitorisch überwachten Ergometertrainings Bei Patienten Mit Einer COPD Nach Exazerbation: Eine Prospektiv Randomisierte Studie
Brief Summary: Home ergometer training combined with online monitoring and regular telephone support could prove to be a cost-effective method to improve physical performance and quality of life in COPD patients.

The primary objective of the study is to demonstrate a significantly higher daily workout time in patients that are monitored during home ergometer training with telephone support compared to conventional home ergometer training. Consequently we expect an increased quality of life related to the illness and a decreasing BODE-Index. A post-interventional lower BODE-Index correlates with a reduced risk of hospitalisation and mortality.


Options:
A: Arm Label: Intervention group "tele-rehabilitation"; Type: EXPERIMENTAL; Interventions: Combination Product: Tele Rehab | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Combination Product: Tele Rehab | Intervention Type: COMBINATION_PRODUCT; Name: Tele Rehab; Assigned to Arm(s): Control, Intervention group "tele-rehabilitation"
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Training with e-health product | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Training with e-health product; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control
C: Arm Label: Self-Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ergometer Training | Arm Label: Motivation; Type: EXPERIMENTAL; Interventions: Other: Ergometer Training, Other: Motivation | Intervention Type: OTHER; Name: Ergometer Training; Assigned to Arm(s): Motivation, Self-Control | Intervention Type: OTHER; Name: Motivation; Assigned to Arm(s): Motivation
D: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Device: ACCESS | Arm Label: paper plan; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ACCESS; Assigned to Arm(s): ACCESS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: German: Effekte Eines Telemonitorisch überwachten Ergometertrainings Bei Patienten Mit Einer COPD Nach Exazerbation: Eine Prospektiv Randomisierte Studie
Brief Summary: Home ergometer training combined with online monitoring and regular telephone support could prove to be a cost-effective method to improve physical performance and quality of life in COPD patients.

The primary objective of the study is to demonstrate a significantly higher daily workout time in patients that are monitored during home ergometer training with telephone support compared to conventional home ergometer training. Consequently we expect an increased quality of life related to the illness and a decreasing BODE-Index. A post-interventional lower BODE-Index correlates with a reduced risk of hospitalisation and mortality.


Options:
A: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health Coaching | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health Coaching; Assigned to Arm(s): Health Coaching
B: Arm Label: Self-Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ergometer Training | Arm Label: Motivation; Type: EXPERIMENTAL; Interventions: Other: Ergometer Training, Other: Motivation | Intervention Type: OTHER; Name: Ergometer Training; Assigned to Arm(s): Motivation, Self-Control | Intervention Type: OTHER; Name: Motivation; Assigned to Arm(s): Motivation
C: Arm Label: HAT; Type: EXPERIMENTAL; Interventions: Behavioral: Home Automated Telemanagement (HAT) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home Automated Telemanagement (HAT); Assigned to Arm(s): HAT
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: B